This Article Figures Only Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (23) Citing Articles via Google Scholar Google Scholar Articles by Frank, R. G. Search for Related Content PubMed PubMed Citation Articles by Frank, R. G. Related Collections Pharmaceuticals Health Spending

Drug Cost Growth

Prescription Drug Prices: Why Do Some Pay More Than Others Do?

The fact that sick elderly people without prescription drug coverage pay far more for drugs than do people with private health insurance has created a call for state and federal governments to take action. Antitrust cases have been launched, state price control legislation has been enacted, and proposals for expansion of Medicare have been offered in response to price and spending levels for prescription drugs. This paper offers an analysis aimed at understanding pricing patterns of brand-name prescription drugs. I focus on the basic economic forces that enable differential pricing of products to exist and show how features of the prescription drug market promote such phenomena. The analysis directs policy attention toward how purchasing practices can be changed to better represent groups that pay the most and are most disadvantaged.

                      What's this?

This article has been cited by other articles:

				A. B. Frakt, S. D. Pizer, and A. M. Hendricks Controlling Prescription Drug Costs: Regulation and the Role of Interest Groups in Medicare and the Veterans Health Administration Journal of Health Politics Policy and Law, December 1, 2008; 33(6): 1079 - 1106. [Abstract] [PDF]

				R. G. Frank and J. P. Newhouse Should Drug Prices Be Negotiated Under Part D Of Medicare? And If So, How? Health Aff., January 1, 2008; 27(1): 33 - 43. [Abstract] [Full Text] [PDF]

				H. A. Huskamp, P. A. Deverka, A. M. Epstein, R. S. Epstein, K. A. McGuigan, A. C. Muriel, and R. G. Frank Impact of 3-Tier Formularies on Drug Treatment of Attention-Deficit/Hyperactivity Disorder in Children Arch Gen Psychiatry, April 1, 2005; 62(4): 435 - 441. [Abstract] [Full Text] [PDF]

				N. K. Choudhry and A. S. Detsky A Perspective on US Drug Reimportation JAMA, January 19, 2005; 293(3): 358 - 362. [Full Text] [PDF]

				H. A. Huskamp, P. A. Deverka, A. M. Epstein, R. S. Epstein, K. A. McGuigan, and R. G. Frank The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending N. Engl. J. Med., December 4, 2003; 349(23): 2224 - 2232. [Abstract] [Full Text] [PDF]

				J. H. Lewis, M. Schonlau, J. A. Munoz, S. M. Asch, M. R. Rosen, H. Yang, and J. J. Escarce Compliance among Pharmacies in California with a Prescription-Drug Discount Program for Medicare Beneficiaries N. Engl. J. Med., March 14, 2002; 346(11): 830 - 835. [Abstract] [Full Text] [PDF]

				J. K. Iglehart Medicare and Prescription Drugs N. Engl. J. Med., March 29, 2001; 344(13): 1010 - 1015. [Full Text] [PDF]